26
|
Garon E, Wong D, Schneider J, Aljumaily R, Korn W, Patel M, Autio K, Papadopoulos K, Naing A, Gabrail N, Munster P, Goldman J, Hung A, Oft M, Leveque J, Spigel D. Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Camidge R, Heist R, Goldman J, Angevin E, Strickler J, Morgensztern D, Barve M, Bauer T, Vokes E, Yi T, Motwani M, Parikh A, Wu J, Kelly K. An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
28
|
Fanelli Kuczmarski M, Sebastian R, Steinfeldt L, Goldman J, Murayi T, Moshfegh A, Zonderman A, Evans M. Flavonoid Intakes of Urban African American and White Adults. J Acad Nutr Diet 2018. [DOI: 10.1016/j.jand.2018.06.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
29
|
Hoy M, Goldman J, Steinfeldt L, Moshfegh A. Comparison of Weight Loss Approaches Used by Adults by Weight Loss Status. J Acad Nutr Diet 2018. [DOI: 10.1016/j.jand.2018.06.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
30
|
Rabe L, Goldman J, Bracken S, Juul J, Meyn L, Hillier S. Prevalence of candida africana among women with Vulvovaginal Candidiasis (VVC) and/or Bacterial Vaginosis (BV) in the United States. Am J Obstet Gynecol 2017. [DOI: 10.1016/j.ajog.2017.08.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Wong D, Schneider J, Aljumaily R, Korn W, Infante J, Patel M, Autio K, Papadopoulos K, Naing A, Gabrail N, Munster P, Goldman J, Ratti N, Van Vlasselaer P, Hung A, Oft M, Garon E. PEGylated human IL-10 (AM0010) in combination with an anti-PD-1 in advanced NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Goldman J, Angevin E, Strickler J, Camidge D, Heist R, Morgensztern D, Barve M, Yue H, Beaulieu J, Motwani M, Afar D, Naumovski L, Kelly K. MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.458] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Langer C, Anderson E, Jotte R, Goldman J, Haggstrom D, Modiano M, Socoteanu M, Smith D, Dahkil C, Konduri K, Kim E, Sanford A, Amiri K, Weiss J. Quality of life (QoL) in elderly NSCLC patients (pts) treated with nab-paclitaxel/carboplatin (nab-P/C) in the ABOUND.70+ trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Garrido Lopez P, Goldman J, Kelly K, Kim E, Beck T, Alonso Garcia M, Yang Z, Ingram KJ, Amstutz L, John W, Provencio Pulla M. Efficacy and safety of abemaciclib combined with either LY3023414 or pembrolizumab in stage IV NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Wong D, Schneider J, Aljumaily R, Korn M, Autio K, Infante J, Patel M, Papadopoulos K, Naing A, Gabrail N, Munster P, Goldman J, Van Vlasselaer P, Hung A, Brown G, Oft M, Garon E. Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Piotrowska Z, Liu E, Varga A, Thakur M, Narayanan V, Liu S, Neal J, Spiegel M, Solomon B, Yu H, Ou SH, Papadimitrakopoulou V, Gadgeel S, Camidge D, Soria JC, Wakelee H, Goldman J, Kopani K, Rolfe L, Sequist L. Rociletinib-associated cataracts in EGFR-mutant NSCLC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Weiss J, Kim E, Amiri K, Anderson E, Dakhil S, Haggstrom D, Jotte R, Konduri K, Modiano M, Ong T, Sanford A, Smith D, Socoteanu M, Goldman J, Langer C. Quality of life (QoL) in elderly patients (pts) with advanced NSCLC treated with nab-paclitaxel (nab-P) + carboplatin (C): Interim results from the ABOUND.70+ study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.81] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Gettinger S, Hellmann M, Shepherd F, Antonia S, Brahmer J, Chow L, Goldman J, Juergens R, Borghaei H, Ready N, Gerber D, Nathan F, Shen Y, Harbison C, Rizvi N. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31737-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Goldman J, Belani C, Novello S, von Pawel J, Csoszi T, Orlov S, Kroll S, Pearce T. Randomized, Double-Blind, Placebo-Controlled Trial of Evofosfamide (TH-302) in Combination with Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv050.46] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Sikorsky N, Schneider V, Goldman J, Leviov M, Leitzin L, Keren S, Steiner M. P294 Breast biopsies during follow up after intraoperative radiotherapy in early breast cancer patients. Breast 2015. [DOI: 10.1016/s0960-9776(15)70326-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
41
|
Soria JC, Sequist L, Goldman J, Wakelee H, Neal J, Camidge R, Gadgeel S, Papadimitrakopoulou V, Dziadziuszko R, Piotrowska Z, Varga A, Solomon B. Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv088.3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Aghion E, Jan L, Meshi L, Goldman J. Increased corrosion resistance of the AZ80 magnesium alloy by rapid solidification. J Biomed Mater Res B Appl Biomater 2014; 103:1541-8. [PMID: 25491147 DOI: 10.1002/jbm.b.33335] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2014] [Revised: 10/06/2014] [Accepted: 11/04/2014] [Indexed: 12/26/2022]
Abstract
Magnesium (Mg) and Mg-alloys are being considered as implantable biometals. Despite their excellent biocompatibility and good mechanical properties, their rapid corrosion is a major impediment precluding their widespread acceptance as implantable biomaterials. Here, we investigate the potential for rapid solidification to increase the corrosion resistance of Mg alloys. To this end, the effect of rapid solidification on the environmental and stress corrosion behavior of the AZ80 Mg alloy vs. its conventionally cast counterpart was evaluated in simulated physiological electrolytes. The microstructural characteristics were examined by optical microscopy, SEM, TEM, and X-ray diffraction analysis. The corrosion behavior was evaluated by immersion, salt spraying, and potentiodynamic polarization. Stress corrosion resistance was assessed by Slow Strain Rate Testing. The results indicate that the corrosion resistance of rapidly solidified ribbons is significantly improved relative to the conventional cast alloy due to the increased Al content dissolved in the α-Mg matrix and the correspondingly reduced presence of the β-phase (Mg17 Al12 ). Unfortunately, extrusion consolidated solidified ribbons exhibited a substantial reduction in the environmental performance and stress corrosion resistance. This was mainly attributed to the detrimental effect of the extrusion process, which enriched the iron impurities and increased the internal stresses by imposing a higher dislocation density. In terms of immersion tests, the average corrosion rate of the rapidly solidified ribbons was <0.4 mm/year compared with ∼2 mm/year for the conventionally cast alloy and 26 mm/year for the rapidly solidified extruded ribbons.
Collapse
|
43
|
Rosen L, Goldman J, Hubbard J, Roos M, Capdevila J, Maynes J, Lin W, O'Keeffe B, Lackner M, Spoerke J, Ware J, Arnieri B, Freas E, Leong S. 382 Phase Ib study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with capecitabine and mFOLFOX6 + bevacizumab in patients with advanced solid tumors and colorectal cancer. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70508-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Rizvi N, Shepherd F, Antonia S, Brahmer J, Chow L, Goldman J, Juergens R, Borghaei H, Ready N, Gerber D, Shen Y, Harbison C, Chen A, Gettinger S. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.08.204] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
45
|
Gettinger S, Rizvi N, Chow L, Borghaei H, Brahmer J, Juergens R, Shepherd F, Laurie S, Gerber D, Goldman J, Shen Y, Harbison C, Chen A, Antonia S. Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu342.7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Zhao B, Tan Y, Tsai W, Lu L, Schwartz L, Lu Z, So J, Goldman J. TU-A-12A-07: CT-Based Biomarkers to Characterize Lung Lesion: Effects of CT Dose, Slice Thickness and Reconstruction Algorithm Based Upon a Phantom Study. Med Phys 2014. [DOI: 10.1118/1.4889253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
47
|
Goldman J. An ethical price tag?: The case of cancer drugs. Eur J Public Health 2013. [DOI: 10.1093/eurpub/ckt126.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
48
|
Pool C, Shankar G, Schantz A, Gunn G, Bolce R, Leirisalo-Repo M, Wang J, Goldman J, DeHoratius R, Fleischmann R, Decktor D. THU0181 Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes after an Active Switch to Infliximab. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Falchook G, Zhou X, Rosen L, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman J, Jung J, Milch C, Sarantopoulos J. Food Effect Study of the Investigational Aurora a Kinase (AAK) Inhibitor MLN8237 (ALISERTIB) in Patients with Advanced Solid Tumors. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33051-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
50
|
Rosen L, Goldman J, Stewart S, Hubbard J, Roos M, Lin W, Shankar G, Capdevila J, Freas E, Leong S. A Phase 1B Study to Evaluate the Safety and Pharmacology of the Dual PI3K-MTOR Inhibitor GDC-0980 in Combination with a Fluoropyrimidine, Oxaliplatin, and Bevacizumab (BEV) in Patients with Advanced Solid Tumors. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33010-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|